杭州浙大迪迅生物基因工程有限公司

　　原標題：對貓進行免疫，以誘導針對人類主要貓過敏原Fel d1的中和抗體
　　①人類對貓的過敏通常是由貓的主要過敏原Fel d1引起的，約10%的西方人群中存在貓過敏。目前，沒有治療貓過敏的有效和安全方法。過敏患者通常的應對方法是盡量避免和貓的接觸或治療他們的過敏癥狀。②我們開發(fā)了一種新的策略，用自身主要過敏原Fel d1對貓進行免疫，來治療人類受試者由Fel d1引起的過敏。③采用重組Fel d 1與來源于黃瓜花葉病毒的病毒樣顆粒組成的聯(lián)合疫苗對貓進行免疫【黃瓜花葉病毒含有破傷風毒素衍生的通用T細胞表位tt830-843 (CuMVTT)】。首次單獨或聯(lián)合使用Fel-CuMVTT疫苗進行耐受性和免疫原性研究，包括增量注射。④該疫苗耐受性良好，沒有明顯的毒性作用。所有的貓都能誘導出強而持久的特異性IgG抗體反應。誘導的抗fel d1抗體具有較高的親和力，在體內(nèi)外均表現(xiàn)出較強的中和能力。內(nèi)源性變應原水平降低，淚液樣本的變應原性降低。⑤給貓接種Fel-CuMVTT可以誘導中和抗體，并可能減少貓主人的過敏癥狀。人類受試者和動物都可以從這種治療中獲益，因為過敏的貓主人可以降低患慢性疾病(如哮喘)的風險，并變得更能容忍他們的貓，因此這些貓可以呆在家里，不需要被送到動物收容所。


延伸閱讀
JACI
Immunization of cats to induce neutralizing antibodies against Fel d 1, the major feline allergen in human subjects
DOI: https://doi.org/10.1016/j.jaci.2019.01.050
Background
Cat allergy in human subjects is usually caused by the major cat allergen Fel d 1 and is found in approximately 10% of the Western population. Currently, there is no efficient and safe therapy for cat allergy available. Allergic patients usually try to avoid cats or treat their allergy symptoms.
Objective
We developed a new strategy to treat Fel d 1–induced allergy in human subjects by immunizing cats against their own major allergen, Fel d 1.
Methods
A conjugate vaccine consisting of recombinant Fel d 1 and a virus-like particle derived from the cucumber mosaic virus containing the tetanus toxin–derived universal T-cell epitope tt830-843 (CuMVTT) was used to immunize cats. A first tolerability and immunogenicity study, including a boost injection, was conducted by using the Fel-CuMVTT vaccine alone or in combination with an adjuvant.
Results
The vaccine was well tolerated and had no overt toxic effect. All cats induced a strong and sustained specific IgG antibody response. The induced anti–Fel d 1 antibodies were of high affinity and exhibited a strong neutralization ability tested both in vitro and in vivo. A reduction in the endogenous allergen level and a reduced allergenicity of tear samples, were observed.
Conclusion
Vaccination of cats with Fel-CuMVTT induces neutralizing antibodies and might result in reduced symptoms of allergic cat owners. Both human subjects and animals could profit from this treatment because allergic cat owners would reduce their risk of developing chronic diseases, such as asthma, and become more tolerant of their cats, which therefore could stay in the households and not need to be relinquished to animal shelters
All Author:
Franziska Thoms , Peter Hunziker Melanie Maudrich Gary T. Jennings Monique Vogel Stefanie Haas Andris Zeltins Regina Hofmann-Lehmann Barbara Riond Jonas Grossmann
Antonia Fettelschoss-Gabriel Gabriela Sen Thomas M. Kündig Martin F. BachmannxMartin
　　創(chuàng)建過敏性疾病的科研、科普知識交流平臺，為過敏患者提供專業(yè)診斷、治療、預防的共享平臺。